Treatment Regimens
The majority of patients (n=136, 85.5%) received systemic medical
therapy (Table 2) and systemic therapy was more common in patients with
KMP versus those without KMP (95.3% vs. 70%, p=0.05). Siro was the
most common treatment (n=51, 32.1%), followed by steroids (n=32,
20.1%), beta-blocker or minimal/none (n=27, 17%), VCR (n=25, 15.7%),
surgical/interventional radiology (IR) (n=17, 10.7%), and Siro+VCR
(n=7, 4.4%). Time from initial symptoms to treatment initiation (16 vs
169 days, p<0.001) and time from diagnosis to treatment
initiation (3 vs. 21 days, p <0.001) were both shorter for
patients with KMP compared to those without KMP. Patients with KMP
received more blood product transfusions (78.1% vs 6.3%,
p<0.001) and more opioid medication use (29.7% vs. 14.7%,
p=0.028). Attempts at surgical procedures or IR embolization were
equivalent across groups (p=0.2).